revumenib
syndax pharma
['revumenib', 'leusm', 'venetoclax', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'augment,data', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'augment-101', 'sndx5613', 'augment,study', 'leukemia', 'myeloid', '2019', 'sndx-5613', 'syndax']
#ash22 #leusm issa: menin inhibitor sndx5613 (revumenib) in rr aml with kmt2ar or npm1m. peds and adults included. heavily pretreated (median 4 prior lines), 82% aml, 16% all, 2% mpal. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)